Restless Legs Syndrome

Clinical guidelines for managing Willis-Ekbom disease, screening for iron deficiency, and dopamine receptor agonist dosing.

⏱️ 4 min read

Table of Contents

🧠 Standard of Care & Symptoms

Restless Legs Syndrome (RLS), also known as Willis-Ekbom Disease, is a sensorimotor neurological disorder characterized by an overwhelming, irresistible urge to move the legs. This urge is usually accompanied by uncomfortable, pulling, creeping, or tingling sensations deep within the limbs.

πŸ” Diagnostic Testing & Ferritin

Diagnosis is primarily clinical, based on a patient meeting the four essential criteria. However, blood work is critical to rule out secondary causes.

Serum Ferritin & Iron Panels

Iron deficiency in the brain is a major driver of RLS pathology. A complete iron panel is mandatory. A **serum ferritin level below 75 mcg/L** is highly indicative of iron-deprived RLS, even if the patient's red blood cell count is normal (non-anemic). Oral or intravenous iron supplementation is recommended to raise ferritin levels above 100 mcg/L.

Secondary Workups

Screening for pregnancy, chronic kidney disease (uremic RLS), and peripheral neuropathy is also recommended, as these conditions can trigger or worsen symptoms.

πŸ’Š Pharmacological & Dopamine Agents

When conservative measures (like iron supplements, avoiding caffeine/alcohol, and leg massage) fail, medications are prescribed.

Alpha-2-Delta Ligands (First-line)

Guidelines now recommend gabapentin enacarbil (Horizant), gabapentin, or pregabalin (Lyrica) as first-line therapies. They stabilize calcium channels in sensory nerves and are preferred because they do not carry the risk of augmentation.

Dopamine Agonists & Augmentation

Dopaminergic agents such as Pramipexole (Mirapex) and Rotigotine (Neupro patch) are highly effective but carry a severe complication known as **augmentation**. With long-term use, the medication causes symptoms to start earlier in the day, spread to the arms, and become more intense. Escalating the dose worsens augmentation, necessitating a slow taper and transition to other classes.

πŸ”¬ Active Clinical Trials

Research focus is on evaluating long-term safety of novel dopamine pathways and assessing safety profiles of newer calcium channel ligands.

Important: Browse actively recruiting clinical trials in our Clinical Trials Catalogue to find a local study.

πŸ—ΊοΈ Next Steps After Diagnosis

If you have recently been diagnosed with Restless Legs Syndrome (RLS), follow these clinical next steps to manage your symptoms:

  1. Request a Full Iron Panel: Ensure your doctor checks serum ferritin, iron, and total iron-binding capacity (TIBC). Target a serum ferritin level of at least 75-100 mcg/L.
  2. Eliminate Dietary Triggers: Completely avoid caffeine, alcohol, and nicotine for at least 2 weeks to evaluate impact on symptom severity.
  3. Review Current Medications: Many common OTC and prescription drugs worsen RLS (e.g. sedating antihistamines like diphenhydramine, and most anti-depressants). Discuss safe alternatives with your doctor.
  4. Establish a Sleep Routine: Keep a cool, quiet sleeping environment, practice moderate evening exercise (avoid heavy workouts right before bed), and try warm baths or leg massages.

❓ Patient FAQ

Q: What is augmentation?
A: Augmentation is a medical phenomenon where taking dopamine agonists (like Pramipexole) for RLS causes RLS symptoms to worsen over time (occurring earlier in the afternoon, spreading to the arms, and becoming more intense). If this occurs, do not increase your dose; contact your doctor to begin a slow taper.

Q: Can caffeine trigger RLS?
A: Yes. Caffeine, alcohol, and nicotine are well-known triggers that worsen RLS symptoms. Eliminating these substances is often the first conservative step in managing mild RLS.

Q: Is RLS hereditary?
A: Yes. Early-onset RLS (diagnosed before age 45) has a very strong genetic component, often running in families. Researchers have identified several specific genetic loci associated with RLS susceptibility.

Get the Free 2026 Clinical AI Directory

Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.

Request Directory via Email

Was this guide helpful?